COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

PHASE4UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions
Heart Failure
Interventions
DRUG

SGLT2i, beta blocker, ARNI, MRA, MTD

"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."

BEHAVIORAL

Education-First

For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT05734690 - COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure | Biotech Hunter | Biotech Hunter